Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Mercedes Lobera, Kevin P. Madauss, Denise Teotico Pohlhaus, et al.
Nature Chemical Biology (2013) Vol. 9, Iss. 5, pp. 319-325
Closed Access | Times Cited: 337

Showing 1-25 of 337 citing articles:

Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta, Jeffrey W. Pollard
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 12, pp. 887-904
Open Access | Times Cited: 1580
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg, Ricky W. Johnstone
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 9, pp. 673-691
Closed Access | Times Cited: 1377
New and emerging HDAC inhibitors for cancer treatment
Alison C. West, Ricky W. Johnstone
Journal of Clinical Investigation (2014) Vol. 124, Iss. 1, pp. 30-39
Open Access | Times Cited: 1256
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li, Edward Seto
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 6, Iss. 10, pp. a026831-a026831
Open Access | Times Cited: 1043
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia
Yue Huang, Rui Su, Yue Sheng, et al.
Cancer Cell (2019) Vol. 35, Iss. 4, pp. 677-691.e10
Open Access | Times Cited: 687
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Madhusoodanan Mottamal, Shilong Zheng, Tien L. Huang, et al.
Molecules (2015) Vol. 20, Iss. 3, pp. 3898-3941
Open Access | Times Cited: 644
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho, Alex H. Y. Chan, A. Ganesan
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12460-12484
Open Access | Times Cited: 571
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Jennifer L. Guerriero, Alaba Sotayo, Holly Ponichtera, et al.
Nature (2017) Vol. 543, Iss. 7645, pp. 428-432
Open Access | Times Cited: 483
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ibraheem Ali, Ryan J. Conrad, Eric Verdin, et al.
Chemical Reviews (2018) Vol. 118, Iss. 3, pp. 1216-1252
Open Access | Times Cited: 303
Inside HDACs with more selective HDAC inhibitors
Joëlle Roche, Philìppe Bertrand
European Journal of Medicinal Chemistry (2016) Vol. 121, pp. 451-483
Closed Access | Times Cited: 294
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
Giorgio Milazzo, Daniele Mercatelli, Giulia Di Muzio, et al.
Genes (2020) Vol. 11, Iss. 5, pp. 556-556
Open Access | Times Cited: 271
Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages
Muhammad Ovais, Mengyu Guo, Chunying Chen
Advanced Materials (2019) Vol. 31, Iss. 19
Closed Access | Times Cited: 265
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Clément Anfray, Aldo Ummarino, Fernando Torres, et al.
Cells (2019) Vol. 9, Iss. 1, pp. 46-46
Open Access | Times Cited: 257
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Jennifer L. Guerriero
Trends in Molecular Medicine (2018) Vol. 24, Iss. 5, pp. 472-489
Open Access | Times Cited: 252
Targeting Metalloenzymes for Therapeutic Intervention
Allie Y. Chen, Rebecca N. Adamek, Benjamin L. Dick, et al.
Chemical Reviews (2018) Vol. 119, Iss. 2, pp. 1323-1455
Open Access | Times Cited: 232
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors—What Some May Have Forgotten or Would Rather Forget?
Sida Shen, Alan P. Kozikowski
ChemMedChem (2015) Vol. 11, Iss. 1, pp. 15-21
Open Access | Times Cited: 219
Zinc binding groups for histone deacetylase inhibitors
Lei Zhang, Jian Zhang, Qixiao Jiang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2018) Vol. 33, Iss. 1, pp. 714-721
Open Access | Times Cited: 195
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Erika Héninger, Timothy Krueger, Joshua M. Lang
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 184
Macrophage targeting in cancer
Martha Lopez‐Yrigoyen, Luca Cassetta, Jeffrey W. Pollard
Annals of the New York Academy of Sciences (2020) Vol. 1499, Iss. 1, pp. 18-41
Open Access | Times Cited: 181
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Kunal Nepali, Jing‐Ping Liou
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 144
Therapeutic targets for cardiac fibrosis: from old school to next-gen
Joshua G. Travers, Charles A. Tharp, Marcello Rubino, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 5
Open Access | Times Cited: 109
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity
Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1362-1391
Closed Access | Times Cited: 107
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 86
Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target
Severin Lechner, Martin Ian P. Malgapo, Christian Grätz, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 8, pp. 812-820
Open Access | Times Cited: 74
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
Raquel García-Vílchez, Ana M. Añazco-Guenkova, Sabine Dietmann, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top